• Mitoxantrone HCl: Decode DNA Damage

  2026-09-02

  Mitoxantrone HCl is a DNA topoisomerase II inhibitor whose effects extend from DNA-break biology to estrogen receptor degradation. This guide presents an assay-centered framework for separating these mechanisms in leukemia, stem cell, and solid-tumor research.

• Triacetin Workflows for Metabolic Research

  2026-09-02

  Triacetin combines short-chain lipid chemistry with practical utility in metabolic, glioblastoma, and ocular research workflows. This guide translates its absorption biology, concentration ranges, formulation behavior, and assay-specific limitations into reproducible experimental decisions.

• One-step TUNEL FITC Apoptosis Detection Kit Guide

  2026-09-01

  Build a reproducible DNA fragmentation workflow for apoptosis detection in tissue sections, adherent cells, and suspension cells. This guide translates a cross-compartment bovine ovarian study into practical assay design, control selection, imaging, flow cytometry, and troubleshooting decisions.

• L-NMMA Acetate in Nitric Oxide Workflows

  2026-09-01

  L-NMMA acetate enables causal testing of nitric oxide signaling rather than simple pathway observation. This practical guide translates dental follicle cell findings into controlled inhibition, dose-response, readout, and troubleshooting workflows for regenerative, inflammation, and vascular research.

• PXDN–LDHA Control of Glioblastoma Glycolysis

  2026-08-31

  A 2026 study in Neurological Research integrates transcriptomic network analysis with cellular and in vivo experiments to identify PXDN as a glycolysis-associated driver of glioblastoma progression. Its rescue experiments place LDHA downstream of PXDN, providing a mechanistic framework for studying metabolic vulnerability alongside malignant behavior.

• Malate Workflows for TCA and Immune Metabolism

  2026-08-30

  Malate enables controlled interrogation of mitochondrial redox balance, TCA-cycle flux, and metabolic crosstalk in tumor–immune models. This workflow-focused guide shows how to use it as a malate dehydrogenase substrate, pathway perturbation reagent, and comparator when translating PDHA1-centered findings into practical assays.

• Naftifine HCl and Translational Mechanism Design

  2026-08-29

  A translational research perspective connecting Naftifine HCl’s target-proximal antifungal biology with the WNT5a/GSK3/β-catenin control of muscle FAP adipogenesis—while clearly separating established evidence from future experimental questions.

• Lung-Targeted Risedronate/Vitamin D3 for Osteoporosis

  2026-08-29

  The reference study developed a pulmonary PAMAM-G5-NH2 dendrimer system co-delivering risedronate sodium and vitamin D3 to improve systemic exposure while reducing the limitations of oral bisphosphonate therapy. In an osteoporosis rat model, the formulation normalized calcium, phosphorus, bone mineral density, WNT-related signals, and selected metabolic changes, providing a mechanistic basis for further lung-targeted bone therapeutics.

• PD98059: A Causal Map for MEK/ERK Assays

  2026-08-28

  PD98059 is a selective and reversible MEK inhibitor for dissecting ERK1/2-dependent proliferation, differentiation, and apoptosis. This article develops an assay-centered framework for separating MEK1/2 biology from parallel ERK5 signaling, with practical implications for leukemia and ischemia research.

• mCherry mRNA for Nanoparticle Assay Design

  2026-08-28

  Learn how mCherry mRNA can serve as more than a fluorescence reporter: it can help dissect nanoparticle loading, delivery, and translation in kidney-targeted workflows.

• Afatinib in Gastric Cancer Assembloids

  2026-08-27

  Afatinib, also known as BIBW 2992, provides an irreversible ErbB-family perturbation tool for comparing epithelial-only organoids with patient-matched tumor–stroma assembloids. This workflow shows how to connect EGFR, HER2, and HER4 pathway measurements with viability, imaging, and transcriptomic readouts while minimizing formulation and model-composition artifacts.

• Mitochondrial Permeability Transition Pore Assay Kit

  2026-08-27

  The Mitochondrial Permeability Transition Pore Assay Kit uses a Calcein AM fluorescent probe and cobalt quenching to measure mitochondrial pore opening in living cells. This article connects assay chemistry with patient-derived disease models, orthogonal validation, and more defensible interpretation of mitochondrial stress data.

• Gastric Cancer Assembloids Model Tumor–Stroma Biology

  2026-08-26

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine matched tumor organoids with tumor-derived stromal subpopulations. The model reproduced clinically relevant epithelial–stromal interactions and showed that stromal composition can alter gene expression and drug sensitivity, supporting more informative studies of resistance and personalized treatment.

• Ibotenic Acid Toxicity in Mice: Dose and Time Effects

  2026-08-26

  A 2026 Toxin Reviews study systematically examines how ibotenic acid exposure alters behavior, blood biochemistry, and brain tissue in mice across dose and time. The work identifies early c-fos activation and reduced Nissl bodies as informative toxicity-associated readouts while showing that neuronal, astrocytic, and microglial counts may remain comparatively stable.

• Triacetin in E-Cigarette Aerosol Aldehyde Formation

  2026-08-25

  The reference study used carbon-13 labeling and NMR spectroscopy to show that triacetin does not simply act as an inert flavor additive during aerosolization. Its hydrolysis releases acetic acid, which promotes degradation of propylene glycol and glycerol and increases aerosol aldehyde products, highlighting the importance of formulation-specific chemistry in inhalation toxicology.

453 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page